Literature DB >> 2225455

Nucleic acid hybridization in viral diagnosis.

M L Landry1.   

Abstract

Since 1982, numerous studies have been published utilizing a variety of hybridization techniques to detect viral nucleic acid directly in clinical specimens and in tissue sections. However, hybridization techniques are still not widely used in the clinical laboratory. Other recent advances, such as the development of monoclonal antibodies for virus identification and ELISA kits for virus detection, and the introduction of centrifugation cultures for rapid diagnosis, have postponed the clinical application of hybridization techniques. Furthermore, the use of hybridization for diagnosis has been limited by its insensitivity when compared to cell culture, the need for radioisotopes to increase sensitivity, and the difficulties inherent in transferring a basic research tool to the clinical laboratory. Nevertheless, with recently developed amplification techniques and further advances in nonradioactive labelling of probes, it can be expected that nucleic acid hybridization will be an established technique in diagnostic laboratories in the near future.

Mesh:

Year:  1990        PMID: 2225455     DOI: 10.1016/0009-9120(90)80053-l

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  Safe-in-Man Broad Spectrum Antiviral Agents.

Authors:  Rouan Yao; Aleksandr Ianevski; Denis Kainov
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  [Procedures of viral identification in respiratory infections].

Authors:  J Aspa; L Cardeñoso
Journal:  Arch Bronconeumol       Date:  1995-11       Impact factor: 4.872

Review 3.  Discovery and development of safe-in-man broad-spectrum antiviral agents.

Authors:  Petter I Andersen; Aleksandr Ianevski; Hilde Lysvand; Astra Vitkauskiene; Valentyn Oksenych; Magnar Bjørås; Kaidi Telling; Irja Lutsar; Uga Dumpis; Yasuhiko Irie; Tanel Tenson; Anu Kantele; Denis E Kainov
Journal:  Int J Infect Dis       Date:  2020-02-17       Impact factor: 3.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.